How Generative AI Can Accelerate Pharma GCCs in India
Drug development is an expensive and high-risk process. The median cost per approved drug can reach up to $2.8 billion, largely due to failures at each stage, from discovery and preclinical research to late-stage clinical trials. Pharmaceutical companies deal with various data sources, including clinical trials, real-world evidence, and patient data, which are often siloed and difficult to integrate. Moreover, incorrect data can result in regulatory issues, such as FDA application denials, leading to major delays in bringing drugs to market and potential damage to the company’s reputation. To navigate these challenges and mitigate risks, pharmaceutical Global Capability Centers (GCCs) are turning to artificial intelligence (AI). For instance, Los Angeles-based Agilisium Consulting complements this journey with its agentic AI solutions like NextGen DLS agent, Content generation, Insight Generation, and Data Observability to accelerate transformation in Pharma GCCs. Agilisium’s Content Generation, built for the life sciences industry, addresses the challenges of creating compliant, precise, and scalable content. It uses AI to automate the development of clinical trial protocols, regulatory submission dossiers, patient narratives, HCP engagement materials, infographics, educational training modules, case report forms (CRFs), drug safety reports, patient recruitment campaigns, post-marketing surveillance reports, grant proposals, and product labeling and packaging content. The platform ensures alignment with regulatory standards like FDA and EMA, reducing time-to-market while maintaining accuracy and compliance. On the other hand, NexGen DataOps Platform is an AI-powered that improves data management in the Life Sciences industry. It uses smart agents to help companies monitor their data, detect issues in real time, and analyse trends. The multi-agent model enables data teams to accelerate time-to-insight, making decision-making more efficient. Additionally, the well-trained LS Co-Pilot provides recommendations for improvements, quickly resolves errors, and automates updates for business teams. It enhances the data-sharing model seamlessly without compromising security. Agilisium’s Insights Generation solution takes data analysis and decision-making in the Life Sciences sector to the next level. It connects to a variety of data sources – from Scientific Journals and Databases, Unstructured Data, Electronic Health Records (EHRs), Genomic and Proteomic Data, Laboratory Information Management Systems (LIMS), Data Warehouses and Knowledge Graphs.This allows organisations to tap into both structured and unstructured data with ease, unlocking deeper insights. With powerful search capabilities, including keyword and full-text search, the platform drastically cuts down the time spent retrieving documents. This means researchers can spend less time searching for data and more time on critical analysis, making their work more efficient and impactful. Agilisium’s Data Observability solution ensures accurate, compliant, and AI-ready data with end-to-end observability. Gain full visibility, detect anomalies in real-time, and enhance data integrity for better decision-making. With no-code onboarding, security-first architecture, and seamless scalability, the solution integrates effortlessly with your existing data stack, providing a single view of data health across lakes, warehouses, ETL, and BI tools. Pharma GCCs can accelerate innovation and reduce significant operation costs by collaborating with GenAI-as-service based solution providers who are exclusively Life Sciences domain lead experts. Agilisium is the preferred AWS partner that emerged as one of the Top 11 AWS Partners with both Life Sciences Consulting Competency and Generative AI Services Competency across the globe. One standout success is Agilisium successfully rearchitected a fortune 500 Biopharma company with AI-powered commercial data lake and data warehouse with end-to-end process automation, resulting in a 75% increase in data processing efficiency and enabling data availability and accessibility for stakeholders but also led to multimillion-dollar annual cost avoidance. All Eyes on India With generative AI now in the picture, data analytics companies are witnessing a change, with companies like ZS Associates, Indegene, Axtria, Zifo and Saama Analytics leading the charge in India. However, Agilisium has been growing steadily in India since its inception in 2014, now employing over 1,050 professionals. The company plans to expand additional 2,000 employees by the end of 2027. A significant part of Agilisium’s growth is the opening of a new facility at Hyderabad’s RMZ Spire campus in Cybercity, a city renowned as India’s pharma hub. This move aims to strengthen Agilisium’s GenAI solutions, evolving them into Agentic AI solutions focused on transforming the Pharma and Life Sciences industries. This new facility will function as both a Global Delivery Centre and a Gen AI Innovation Centre of Excellence. The city’s strong pharmaceutical centric business expansion and proximity to Genome Valley make it an ideal location for this expansion. Today, GCCs are a major part of India’s IT and services sector, employing over 1.6 million people. According to EY, this growth will continue, with over 2,400 GCCs expected to create jobs for about 4.5 million people by 2030. The market size is expected to grow from $45 billion now to $110 billion by 2030. According to a recent report, GCCs in India are hiring 30% more fresher and entry-level talent from colleges and off-campus sources to expand the talent pool and secure more affordable talent. With rising demand for data and analytics skills in service offerings, 51% of GCCs are prioritising technology and AI reskilling for growth, according to EY. Agilisium offers a Build-Operate-Transfer (BOT) model that enables companies to design and develop a state-of-the-art Centre of Excellence for technology teams with the top 1% of talent, who are trained in Life Sciences domain knowledge. Agilisium has 20+ F500 & Global 2000 Biopharma companies, offering them support in enhancing the entire pharma-vale chain through developing future-proof Gen AI solutions through Agilisium Labs, an Innovation unit of Agilisium.
By combining AI tools and fast talent scaling, Agilisium is helping pharma companies overcome data barriers.
Drug development is an expensive and high-risk process. The median cost per approved drug can reach up to $2.8 billion, largely due to failures at each stage, from discovery and preclinical research to late-stage clinical trials. 
["GCCs"]
["knowledge graphs", "GenAI", "artificial intelligence", "agentic AI", "AWS", "AI", "ML", "Aim", "analytics", "generative AI", "GCCs"]
["AI", "artificial intelligence", "ML", "analytics", "generative AI", "GenAI", "agentic AI", "Aim", "knowledge graphs", "AWS"]
Siddharth is a media graduate who loves to explore tech through journalism and putting forward ideas worth pondering about in the era of artificial intelligence.